Beneficial effects of N-acetylcysteine on systemic lupus erythematosus disease activityand its associated complications

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181030041500N2

Enrollment

Registered

2019-07-08

Start date

2014-06-22

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus erythromatosis. Systemic lupus erythematosus (SLE)

Interventions

Intervention 1: Control group: the patients continue standard drugs protocol. Intervention 2: Intervention group: the patients receive 1800 mg NAC ( made by osveh drug company, 600 mg tab ) for 3 mont

Eligibility

Sex/Gender

All

Age

16 Years to No maximum

Inclusion criteria

Inclusion criteria: Age more than 16 Having lupus History of using prednisone, azathioprine, mycophenolate mofetil Satisfaction with participation in the study

Exclusion criteria

Exclusion criteria: Pregnant or lactating patients Having any disease at the same time History of chronic infections Bronchiectasis Infection in last month History of severe infections or frequent infections Smoking Patients with excessive use of antioxidants (daily and without Prescription) and acetaminophen Acute SLE flares threatening vital organs People in need of treatment with intravenous cyclophosphamide Patients who are candidates for biological drugs rituximab, abatacept Dissatisfaction for participation in the study

Design outcomes

Primary

Measure	Time frame
The activity of lupus disease. Timepoint: At the beginning of study and 3 months later. Method of measurement: SLEDAI and BILAG scoring protocol.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPooya Saeed Askari

Rafsanjan University of Medical Sciences

Pooyasaeedaskary@gmail.com+98 34 3428 0038

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026